The NUVEEN PA INVT (NQP) to Issue Monthly Dividend of $0.06 on February 1st

The NUVEEN PA INVT (NQP) to Issue Monthly Dividend of $0.06 on  February 1st

NUVEEN PA INVT (NYSE:NQP) declared a monthly dividend on Wednesday, January 4th. Shareholders of record on Friday, January 13th will be paid a dividend of 0.0585 per share on Wednesday, February 1st. This represents a $0.70 annualized dividend and a yield of 5.31%. The ex-dividend date of this dividend is Wednesday, January 11th. NUVEEN PA INVT (NYSE:NQP) opened at 13.21 on Friday. NUVEEN PA INVT has a 52 week low of $12.90 and a 52 week high of $15.66. The firm has a 50-day moving average of $13.08 and a…

The Nuveen Select Tax Free Income Portfolio III (NXR) To Go Ex-Dividend on January 11th

The Nuveen Select Tax Free Income Portfolio III (NXR) To Go Ex-Dividend on January 11th

Nuveen Select Tax Free Income Portfolio III (NYSE:NXR) declared a monthly dividend on Wednesday, January 4th. Shareholders of record on Friday, January 13th will be given a dividend of 0.0435 per share by the investment management company on Wednesday, February 1st. This represents a $0.52 dividend on an annualized basis and a yield of 3.67%. The ex-dividend date of this dividend is Wednesday, January 11th. Nuveen Select Tax Free Income Portfolio III (NYSE:NXR) opened at 14.21 on Friday. The firm has a 50-day moving average of $13.99 and a 200-day…

The Nuveen Select Tax Free Income Portfolio (NXP) To Go Ex-Dividend on January 11th

The Nuveen Select Tax Free Income Portfolio (NXP) To Go Ex-Dividend on January 11th

Nuveen Select Tax Free Income Portfolio (NYSE:NXP) announced a monthly dividend on Wednesday, January 4th. Stockholders of record on Friday, January 13th will be given a dividend of 0.0455 per share on Wednesday, February 1st. This represents a $0.55 dividend on an annualized basis and a dividend yield of 3.87%. The ex-dividend date of this dividend is Wednesday, January 11th. Shares of Nuveen Select Tax Free Income Portfolio (NYSE:NXP) opened at 14.11 on Friday. The stock has a 50 day moving average of $13.78 and a 200-day moving average of…

The Forum Energy Technologies, Inc. (FET) CFO James Whelan Harris Sells 20,000 Shares of Stock

The Forum Energy Technologies, Inc. (FET) CFO James Whelan Harris Sells 20,000 Shares of Stock

Forum Energy Technologies, Inc. (NYSE:FET) CFO James Whelan Harris sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, January 4th. The stock was sold at an average price of $24.00, for a total transaction of $480,000.00. Following the sale, the chief financial officer now owns 283,306 shares of the company’s stock, valued at $6,799,344. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Forum Energy Technologies, Inc. (NYSE:FET) opened at 23.80 on Friday. The firm’s market…

The Workday, Inc. (WDAY) Director Michael M. Mcnamara Sells 6,666 Shares of Stock

The Workday, Inc. (WDAY) Director Michael M. Mcnamara Sells 6,666 Shares of Stock

Workday, Inc. (NYSE:WDAY) Director Michael M. Mcnamara sold 6,666 shares of the firm’s stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $70.49, for a total value of $469,886.34. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Michael M. Mcnamara also recently made the following trade(s): Workday, Inc. (NYSE:WDAY) opened at 72.28 on Friday. The stock has a 50 day moving average of $73.81 and a 200 day moving average of $81.31….

The Northwest Bancshares, Inc. (NWBI) Shares Bought by BlackRock Fund Advisors

The Northwest Bancshares, Inc. (NWBI) Shares Bought by BlackRock Fund Advisors

BlackRock Fund Advisors boosted its position in shares of Northwest Bancshares, Inc. (NASDAQ:NWBI) by 12.3% during the third quarter, Holdings Channel reports. The fund owned 7,369,940 shares of the company’s stock after buying an additional 807,120 shares during the period. BlackRock Fund Advisors owned about 0.07% of Northwest Bancshares worth $115,782,000 as of its most recent filing with the SEC. Other large investors have also recently modified their holdings of the company. Creative Planning boosted its stake in shares of Northwest Bancshares by 12.8% in the third quarter. Creative Planning…

The BlackRock Fund Advisors Has $117,957,000 Position in ITT Inc. (ITT)

The BlackRock Fund Advisors Has $117,957,000 Position in ITT Inc. (ITT)

BlackRock Fund Advisors boosted its stake in ITT Inc. (NYSE:ITT) by 4.2% during the third quarter, Holdings Channel reports. The fund owned 3,291,216 shares of the company’s stock after buying an additional 133,645 shares during the period. BlackRock Fund Advisors’ holdings in ITT were worth $117,957,000 as of its most recent filing with the SEC. Several other institutional investors have also recently modified their holdings of ITT. Creative Planning raised its position in shares of ITT by 10.5% in the second quarter. Creative Planning now owns 5,293 shares of the…

The Willis Towers Watson Public Limited Company (WLTW) Shares Bought by Clarkston Capital Partners LLC

The Willis Towers Watson Public Limited Company (WLTW) Shares Bought by Clarkston Capital Partners LLC

Clarkston Capital Partners LLC boosted its position in Willis Towers Watson Public Limited Company (NASDAQ:WLTW) by 11.5% during the third quarter, Holdings Channel reports. The firm owned 847,827 shares of the company’s stock after buying an additional 87,498 shares during the period. Willis Towers Watson Public Limited Company comprises approximately 5.4% of Clarkston Capital Partners LLC’s investment portfolio, making the stock its 2nd largest position. Clarkston Capital Partners LLC’s holdings in Willis Towers Watson Public Limited Company were worth $112,566,000 at the end of the most recent reporting period. A…

The Sumitomo Mitsui Trust Holdings Inc. Sells 553 Shares of McKesson Corporation (MCK)

The Sumitomo Mitsui Trust Holdings Inc. Sells 553 Shares of McKesson Corporation (MCK)

Sumitomo Mitsui Trust Holdings Inc. lowered its stake in McKesson Corporation (NYSE:MCK) by 0.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 650,399 shares of the company’s stock after selling 553 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in McKesson Corporation were worth $108,454,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors also recently bought and sold shares of MCK. Boston Partners raised its position in…

The CME Group Inc. (CME) Shares Sold by Sumitomo Mitsui Trust Holdings Inc.

The CME Group Inc. (CME) Shares Sold by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. reduced its position in shares of CME Group Inc. (NASDAQ:CME) by 0.6% during the third quarter, Holdings Channel reports. The firm owned 1,129,931 shares of the company’s stock after selling 7,303 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in CME Group were worth $118,100,000 as of its most recent SEC filing. Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in CME Group by 2.1% in the second quarter. Vanguard Group Inc. now…

The Bayer AG’s (BAYN) “Buy” Rating Reaffirmed at Citigroup Inc.

The Bayer AG’s (BAYN) “Buy” Rating Reaffirmed at Citigroup Inc.

Bayer AG (FRA:BAYN)‘s stock had its “buy” rating reiterated by equities researchers at Citigroup Inc. in a report released on Friday. A number of other equities research analysts have also issued reports on the stock. Bankhaus Lampe set a €103.00 ($107.29) price target on shares of Bayer AG and gave the stock a “buy” rating in a report on Wednesday, October 26th. BNP Paribas set a €103.00 ($107.29) price target on shares of Bayer AG and gave the stock a “neutral” rating in a report on Monday, October 24th. DZ…

The Fred’s, Inc. (FRED) Raised to “Equal Weight” at Stephens

The Fred’s, Inc. (FRED) Raised to “Equal Weight” at Stephens

Fred’s, Inc. (NASDAQ:FRED) was upgraded by analysts at Stephens from an “underweight” rating to an “equal weight” rating in a note issued to investors on Friday, The Fly reports. Several other equities research analysts have also recently weighed in on FRED. Deutsche Bank AG restated a “hold” rating and issued a $23.00 price target (up previously from $8.00) on shares of Fred’s in a research report on Friday, December 23rd. MKM Partners restated a “neutral” rating and issued a $22.00 price target (up previously from $9.00) on shares of Fred’s…

The CardConnect Corp. (CCN) Coverage Initiated by Analysts at William Blair

The CardConnect Corp. (CCN) Coverage Initiated by Analysts at William Blair

Investment analysts at William Blair initiated coverage on shares of CardConnect Corp. (NASDAQ:CCN) in a research report issued on Friday, The Fly reports. The firm set an “outperform” rating on the stock. CCN has been the subject of several other reports. Cantor Fitzgerald set a $12.00 price objective on CardConnect Corp. and gave the company a “buy” rating in a research note on Friday, November 11th. BTIG Research reaffirmed a “buy” rating and issued a $14.00 target price on shares of CardConnect Corp. in a research note on Sunday, November…

The Allianz SE (AZSEY) Upgraded by Zacks Investment Research to Hold

The Allianz SE (AZSEY) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Allianz SE (OTCMKTS:AZSEY) from a sell rating to a hold rating in a research report released on Thursday. According to Zacks, “Allianz AG’s principal activities are carried out through four divisions: Life/Health: Provides any of life and heath insurances; Property/Casualty: Provides property and casualty insurance, travel insurance and credit insurance; Banking: Provides a range of banking services, including lending, deposit taking, investment banking; Asset Management: Asset Management for third party investor and Asset under Management which cover the owners investments. “ AZSEY has been…

The Expedia, Inc. (EXPE) Upgraded by Stifel Nicolaus to Buy

The Expedia, Inc. (EXPE) Upgraded by Stifel Nicolaus to Buy

Stifel Nicolaus upgraded shares of Expedia, Inc. (NASDAQ:EXPE) from a hold rating to a buy rating in a research report sent to investors on Thursday morning. They currently have $130.00 price target on the online travel company’s stock. Other equities analysts also recently issued reports about the stock. Benchmark Co. upped their price target on shares of Expedia from $135.00 to $150.00 and gave the company a buy rating in a research note on Monday, October 24th. Cantor Fitzgerald reiterated a buy rating and set a $175.00 price objective on…

The Agree Realty Corporation (ADC) Upgraded by Zacks Investment Research to “Hold”

The Agree Realty Corporation (ADC) Upgraded by Zacks Investment Research to “Hold”

Zacks Investment Research upgraded shares of Agree Realty Corporation (NYSE:ADC) from a sell rating to a hold rating in a research note released on Thursday. According to Zacks, “Agree Realty Corp. is a self-administered, self-managed real estate investment trust which develops, acquires, owns and operates properties which are primarily leased to major national and regional retail companies under net leases. “ Several other equities analysts also recently commented on ADC. FBR & Co started coverage on shares of Agree Realty Corporation in a report on Wednesday, October 12th. They issued…

The BeiGene, Ltd. (BGNE) Upgraded to “Buy” by Zacks Investment Research

The BeiGene, Ltd. (BGNE) Upgraded to “Buy” by Zacks Investment Research

Zacks Investment Research upgraded shares of BeiGene, Ltd. (NASDAQ:BGNE) from a hold rating to a buy rating in a research note published on Thursday morning. Zacks Investment Research currently has $36.00 price target on the stock. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “ BGNE has been the subject of a number of other research reports. Maxim Group set a $41.00 target price…

The Genocea Biosciences, Inc. (GNCA) Lowered to “Hold” at Zacks Investment Research

The Genocea Biosciences, Inc. (GNCA) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) from a buy rating to a hold rating in a report issued on Thursday. According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “ Several other equities analysts have also weighed…

The Community Health Systems, Inc. (CYH) Debt Trading 2.8% Higher

The Community Health Systems, Inc. (CYH) Debt Trading 2.8% Higher

An issue of Community Health Systems, Inc. (NYSE:CYH) debt rose 2.8% as a percentage of its face value during trading on Wednesday. The high-yield issue of debt has a 6.875% coupon and is set to mature on February 1, 2022. The debt is now trading at $72.75 and was trading at $70.18 last week. Price moves in a company’s debt in credit markets sometimes predict parallel moves in its share price. A number of equities analysts have commented on CYH shares. Vetr lowered Community Health Systems from a “strong-buy” rating…

The Alnylam Pharmaceuticals, Inc. (ALNY) Downgraded to “Buy” at Vetr Inc.

The Alnylam Pharmaceuticals, Inc. (ALNY) Downgraded to “Buy” at Vetr Inc.

Vetr cut shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday. They currently have $46.27 price target on the biopharmaceutical company’s stock. Other research analysts also recently issued reports about the stock. Jefferies Group decreased their price target on shares of Alnylam Pharmaceuticals from $86.00 to $58.00 and set a buy rating on the stock in a research note on Thursday, October 6th. Needham & Company LLC cut shares of Alnylam Pharmaceuticals to a buy rating…